Shanghai Guangsheng Biopharmaceutical

Shanghai Guangsheng Biopharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative photodynamic therapy (PDT) and sonodynamic therapy (SDT) for oncology. The company's lead asset, Cosiporfin Sodium (also known as DVDMS or Sinoporphyrin Sodium), is a novel porphyrin-based photosensitizer designed to exhibit high tumor selectivity and potent anti-tumor activity upon activation by specific light or ultrasound wavelengths. Currently, Cosiporfin Sodium is in Phase 3 clinical trials for advanced esophageal cancer and Phase 2/3 trials for extrahepatic cholangiocarcinoma. Shanghai Guangsheng collaborates extensively with leading academic institutions, such as Peking University Cancer Hospital, to advance its pipeline of targeted therapies for solid tumors.